Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
2011-08-02
2011-08-02
Parkin, Jeffrey (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
C424S208100, C435S069100
Reexamination Certificate
active
07989161
ABSTRACT:
A method for determining sensitivity or resistance of isolates of HIV (human immunodeficiency virus) retroviruses to chemical molecules having an inhibiting activity on a viral protease or to therapeutic treatments based on inhibitors of the viral protease, including causing cell lysis of at least one yeast by expression of the retrovirus protease.
REFERENCES:
patent: 5413914 (1995-05-01), Franzusoff
patent: 2 729 973 (1996-08-01), None
Hertogs et al. A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs. Antimicrobial Agents and Chemotherapy, Feb. 1998, vol. 42, No. 2, p. 269-276.
M'Barek et al. HIV-2 Protease resistance defined in yeast cells. Retrovirology 2006, vol. 3, p. 58-66.
Gustchina et al. Comparative Analysis of the Sequences and Structures of HIV-1 and HIV-2 Proteases. Proteins 1991, vol. 10, p. 325-339.
Loffert et al. PCR optimization: primer design. QIAGEN News, 1997, Issue No. 5, p. 1 and 4-6.
Blanco, R., et al., 2003, Cell killing by HIV-1 protease, J. Biol. Chem. 278(2):1086-1093.
Pieniazek, D et al 2004, HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1, AIDS 18:495-502.
Liu, H., et al., 1992, Construction of a GAL1-regulated yeast cDNA expression library and its application to the identification of genes whose overexpression causes lethality in yeast, Genetics 132:665-673.
Blanco, R., et al., 2003, Cell killing by HIV-1 protease. J. Biol. Chem. 278(2):1086-1093.
M/Barek, N. B., et al., 2006, HIV-2 protease resistance defined in yeast cells. Retrovirol. 3(58):1-9.
Tomasselli, A. G., et al., 1991, Actin, troponin C, alzheimer amyloid precursor protein and pro-interleukin 1 beta as substrates of the protease from human immunodeficiency virus. J. Biol. Chem. 266(22):14548-14553.
Blanco Raquel et al., “Cell Killing by HIV-1 Protease,” J. of Biol. Chem., vol. 278, Issue 2, Jan. 10, 2003, pp. 1086-1093 (Abstract Only).
Liu Haoping et al., “Construction of a GAL1-Regulated Yeast cDNA Expression Library and Its Application to the Identification of Genes Whose Overexpression Causes Lethality in Yeast,” Genetics Society of America, vol. 132, No. 3, 1992, pp. 665-673.
Angel Barco et al., “Poliovirus 2A-Pro-Expression Inhibits Growth of Yeast Cells,” FEBS Letters, vol. 371, 1995, pp. 4-8.
M. G. Murray et al., “Inactivation of a Yeast Transactivator by the Fused HIV-1 Proteinase: a Simple Assay for Inhibitors of the Viral Enzyme Activity,” Gene, Elsevier Biomedical Press, Amsterdam, NL, vol. 134, No. 1, 1993, pp. 123-128 (Abstract Only).
Adjorlolo-Johnson, G. et al., “Prospective Comparison of Mother-to-Child Transmission of HIV-1 and HIV-2 in Abidjan, Ivory Coast,”JAMA,Aug. 10, 1994; vol. 272, No. 6, pp. 462-466.
Ancelle, R. et al., “Long Incubation Period for HIV-2 Infection,”The Lancet,Mar. 21, 1987, pp. 688-689.
Andersson, S. et al., “Plasma Viral Load in HIV-1 and HIV-2 Singly and Dually Infected Individuals in Guinea-Bissau, West Africa: Significantly Lower Plasma Virus Set Point in HIV-2 Infection Than in HIV-1 Infection,”Arch. Intern. Med.,Nov. 27, 2000, vol. 160, pp. 3286-3293.
Boross, P. et al., “Effect of Substrate Residues on the P2′ Preference of Retroviral Proteinases,”Eur. J. Biochem.,1999, vol. 264, pp. 921-929.
Büttner, J. et al., “Screening of Inhibitors of HIV-1 Protease Using anEscherichia coliCell Assay,”Biochemical and Biophysical Research Communications,1997, vol. 233, No. 1, pp. 36-38.
Clavel, F. et al., “Isolation of a New Human Retrovirus from West African Patients with AIDS,”Science,Jul. 18, 1986, vol. 233, pp. 343-346.
Clavel, F. et al., “Molecular Cloning and Polymorphism of the Human Immune Deficiency Virus Type 2,”Nature,Dec. 1986, vol. 324, pp. 691-695.
Langley, C.L. et al., “HIV-1, HIV-2, Human Papillomavirus Infection and Cervical Neoplasia in High-Risk African Women,”AIDS,1996, vol. 10, No. 4, pp. 413-417.
Marlink, R. et al., “Reduced Rate of Disease Development After HIV-2 Infection as Compared to HIV-1,”Science,Sep. 9, 1994, vol. 265, No. 5178, pp. 1587-1590.
Marlink, R., “Lessons from the Second AIDS Virus, HIV-2,”AIDS,1996, vol. 10, pp. 689-699.
Moody, M.D et al., “A Side Chain at Position 48 of the Human Immunodeficiency Virus Type-1 Protease Flap Provides an Additional Specificity Determinant,”Virology,1995, vol. 207, pp. 475-485.
Oroszlan, S. et al., “Retroviral Proteinases,”Current Topics in Microbiology and Immunology,1990, vol. 157, pp. 153-185.
Palella, F.J. et al., “Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection,”The New England Journal of Medicine,Mar. 26, 1998, vol. 338, No. 13, pp. 853-860.
Pettit, S.C. et al., “Analysis of Retroviral Protease Cleavage Sites Reveals Two Types of Cleavage Sites and the Structural Requirements of the P1 Amino Acid,”The Journal of Biological Chemistry,Aug. 5, 1991, vol. 266, No. 22, pp. 14539-14547.
Pettit, S.C. et al., “The p2 Domain of Human Immunodeficiency Virus Type 1 Gag Regulates Sequential Proteolytic Processing and Is Required to Produce Fully Infectious Virions,”Journal of Virology,Dec. 1994, vol. 68, No. 22, pp. 8017-8027.
Popper, S. J. et al., “Lower Human Immunodeficiency Virus (HIV) Type 2 Viral Load Reflects the Difference in Pathogenicity of HIV-1 and HIV-2,”The Journal of Infectious Diseases,Oct. 1999, vol. 180, pp. 1116-1121.
Poulsen, A-G. et al., “Prevalence of and Mortality from Human Immunodeficiency Virus Type 2 in Bissau, West Africa,”The Lancet,Apr. 15, 1989, pp. 827-830.
Soriano, V. et al., “Human Immunodeficiency Virus Type 2 (HIV-2) in Portugal: Clinical Spectrum, Circulating Subtypes, Virus Isolation, and Plasma Viral Load,”Journal of Medical Virology,2000, vol. 61, pp. 111-116.
Vittinghoff, E. et al., “Combination Antiretroviral Therapy and Recent Declines in AIDS Incidence and Mortality,”The Journal of Infectious Diseases,1999, vol. 179, pp. 717-720.
Wilkins, A. et al., “The Epidemiology of HIV Infection in a Rural Area of Guinea-Bissau,”AIDS,1993, vol, 7, No. 8, pp. 1119-1122.
Audoly Gilles
Ben M'Barek Najoua
Gluschankof Pablo
Raoult Didier
Centre National de la Recherche Scientifique "CNRS"
DLA Piper (LLP) US
Parkin Jeffrey
Université de la Méditérranée
LandOfFree
Methods for determining human immunodeficiency virus type 2... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for determining human immunodeficiency virus type 2..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for determining human immunodeficiency virus type 2... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2638433